## **Dawood Darbar**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4360634/publications.pdf

Version: 2024-02-01

190 papers 14,782 citations

<sup>26630</sup>
56
h-index

20961 115 g-index

201 all docs

201 docs citations

times ranked

201

17207 citing authors

#	Article	IF	CITATIONS
1	Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. Nature, 2021, 590, 290-299.	27.8	1,069
2	2012 ACCF/AHA/HRS Focused Update Incorporated Into the ACCF/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. Circulation, 2013, 127, e283-352.	1.6	803
3	2012 ACCF/AHA/HRS Focused Update Incorporated Into the ACCF/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. Journal of the American College of Cardiology, 2013, 61, e6-e75.	2.8	736
4	Multi-ethnic genome-wide association study for atrial fibrillation. Nature Genetics, 2018, 50, 1225-1233.	21.4	552
5	Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nature Genetics, 2012, 44, 670-675.	21.4	533
6	Prevention of Atrial Fibrillation. Circulation, 2009, 119, 606-618.	1.6	446
7	Common variants in KCNN3 are associated with lone atrial fibrillation. Nature Genetics, 2010, 42, 240-244.	21.4	438
8	A sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic stroke. Nature Genetics, 2009, 41, 876-878.	21.4	434
9	Metabolic Syndrome and Risk of Development of Atrial Fibrillation. Circulation, 2008, 117, 1255-1260.	1.6	378
10	Inherited causes of clonal haematopoiesis in 97,691 whole genomes. Nature, 2020, 586, 763-768.	27.8	376
11	Drug-Induced Long QT Syndrome. Pharmacological Reviews, 2010, 62, 760-781.	16.0	374
12	2012 ACCF/AHA/HRS Focused Update of the 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. Journal of the American College of Cardiology, 2012, 60, 1297-1313.	2.8	335
13	2012 ACCF/AHA/HRS Focused Update of the 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. Circulation, 2012, 126, 1784-1800.	1.6	321
14	Familial atrial fibrillation is a genetically heterogeneous disorder. Journal of the American College of Cardiology, 2003, 41, 2185-2192.	2.8	309
15	Atrial Natriuretic Peptide Frameshift Mutation in Familial Atrial Fibrillation. New England Journal of Medicine, 2008, 359, 158-165.	27.0	300
16	Cardiac Sodium Channel ( <i>SCN5A</i> ) Variants Associated with Atrial Fibrillation. Circulation, 2008, 117, 1927-1935.	1.6	292
17	Identification of heart rate–associated loci and their effects on cardiac conduction and rhythm disorders. Nature Genetics, 2013, 45, 621-631.	21.4	282
18	Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation. Nature Genetics, 2017, 49, 946-952.	21.4	279

#	Article	IF	CITATIONS
19	A rare variant in MYH6 is associated with high risk of sick sinus syndrome. Nature Genetics, 2011, 43, 316-320.	21.4	275
20	Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm, 2010, 7, 438-444.	0.7	270
21	2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, e153-e193.	0.8	236
22	Mutations in Sodium Channel $\hat{l}^21$ - and $\hat{l}^22$ -Subunits Associated With Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2009, 2, 268-275.	4.8	212
23	Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. European Heart Journal, 2008, 30, 813-819.	2.2	193
24	Integrating Genetic, Transcriptional, and Functional Analyses to Identify 5 Novel Genes for Atrial Fibrillation. Circulation, 2014, 130, 1225-1235.	1.6	183
25	Assessing the contribution of rare variants to complex trait heritability from whole-genome sequence data. Nature Genetics, 2022, 54, 263-273.	21.4	156
26	The APPLE score: a novel and simple score for the prediction of rhythm outcomes after catheter ablation of atrial fibrillation. Clinical Research in Cardiology, 2015, 104, 871-876.	3.3	147
27	Relation of the Severity of Obstructive Sleep Apnea in Response to Anti-Arrhythmic Drugs in Patients With Atrial Fibrillation or Atrial Flutter. American Journal of Cardiology, 2012, 110, 369-372.	1.6	144
28	Association Between Titin Loss-of-Function Variants and Early-Onset Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2018, 320, 2354.	7.4	144
29	Diagnostic Value of B-Type Natriuretic Peptide Concentrations in Patients With Acute Myocardial Infarction. American Journal of Cardiology, 1996, 78, 284-287.	1.6	123
30	Symptomatic Response to Antiarrhythmic Drug Therapy Is Modulated by a Common Single Nucleotide Polymorphism in Atrial Fibrillation. Journal of the American College of Cardiology, 2012, 60, 539-545.	2.8	118
31	Atrial Fibrillation Is an Independent Predictor of Mortality in Critically Ill Patients*. Critical Care Medicine, 2015, 43, 2104-2111.	0.9	114
32	Role of common and rare variants in <i>SCN10A</i> : results from the Brugada syndrome QRS locus gene discovery collaborative study. Cardiovascular Research, 2015, 106, 520-529.	3.8	108
33	Variation in the 4q25 Chromosomal Locus Predicts Atrial Fibrillation After Coronary Artery Bypass Graft Surgery. Circulation: Cardiovascular Genetics, 2009, 2, 499-506.	5.1	104
34	A KCNJ8 mutation associated with early repolarization and atrial fibrillation. Europace, 2012, 14, 1428-1432.	1.7	103
35	Common Genetic Variants and Response to Atrial Fibrillation Ablation. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 296-302.	4.8	98
36	Unmasking of Brugada Syndrome by Lithium. Circulation, 2005, 112, 1527-1531.	1.6	96

#	Article	IF	CITATIONS
37	Voltage-Gated Sodium Channels: Biophysics, Pharmacology, and Related Channelopathies. Frontiers in Pharmacology, 2012, 3, 124.	3.5	95
38	Polymorphism modulates symptomatic response to antiarrhythmic drug therapy in patients with lone atrial fibrillation. Heart Rhythm, 2007, 4, 743-749.	0.7	92
39	Genetic Risk Prediction of Atrial Fibrillation. Circulation, 2017, 135, 1311-1320.	1.6	87
40	Exaggerated QT prolongation after cardioversion of atrial fibrillation. Journal of the American College of Cardiology, 1999, 34, 396-401.	2.8	86
41	Augmented potassium current is a shared phenotype for two genetic defects associated with familial atrial fibrillation. Journal of Molecular and Cellular Cardiology, 2010, 48, 181-190.	1.9	85
42	A Common $\hat{I}^21$ -Adrenergic Receptor Polymorphism Predicts Favorable Response to Rate-Control Therapy in Atrial Fibrillation. Journal of the American College of Cardiology, 2012, 59, 49-56.	2.8	84
43	Common genetic polymorphism at 4q25 locus predicts atrial fibrillation recurrence after successful cardioversion. Heart Rhythm, 2013, 10, 849-855.	0.7	82
44	Chromosome 4q25 Variants Are Genetic Modifiers of Rare Ion Channel Mutations Associated With Familial Atrial Fibrillation. Journal of the American College of Cardiology, 2012, 60, 1173-1181.	2.8	80
45	Sensitivity and specificity of QTc dispersion for identification of risk of cardiac death in patients with peripheral vascular disease. BMJ: British Medical Journal, 1996, 312, 874-878.	2.3	80
46	P Wave Signal-Averaged Electrocardiography to Identify Risk for Atrial Fibrillation. PACE - Pacing and Clinical Electrophysiology, 2002, 25, 1447-1453.	1.2	77
47	Genetic mechanisms of atrial fibrillation: impact on response to treatment. Nature Reviews Cardiology, 2013, 10, 317-329.	13.7	76
48	A Missense Variant in PLEC Increases RiskÂof Atrial Fibrillation. Journal of the American College of Cardiology, 2017, 70, 2157-2168.	2.8	73
49	Novel KCNA5 mutation implicates tyrosine kinase signaling in human atrial fibrillation. Heart Rhythm, 2010, 7, 1246-1252.	0.7	70
50	2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. Executive summary. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 772-791.	0.8	69
51	Ictal Asystole and Ictal Syncope. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 159-164.	4.8	68
52	Early-Onset Atrial Fibrillation and the Prevalence of Rare Variants in Cardiomyopathy and Arrhythmia Genes. JAMA Cardiology, 2021, 6, 1371.	6.1	66
53	SCN10A/Nav1.8 modulation of peak and late sodium currents in patients with early onset atrial fibrillation. Cardiovascular Research, 2014, 104, 355-363.	3.8	65
54	Effect of Peripheral Arterial Disease in Patients Undergoing Percutaneous Coronary Intervention With Intracoronary Stents. Mayo Clinic Proceedings, 2004, 79, 1113-1118.	3.0	61

#	Article	IF	Citations
55	Prolonged Signal-Averaged P-Wave Duration as an Intermediate Phenotype for Familial Atrial Fibrillation. Journal of the American College of Cardiology, 2008, 51, 1083-1089.	2.8	59
56	A Clinical Prediction Model to Estimate Risk for 30-Day Adverse Events in Emergency Department Patients With Symptomatic Atrial Fibrillation. Annals of Emergency Medicine, 2011, 57, 1-12.	0.6	56
57	Relation of Morbid Obesity and Female Gender to Risk of Procedural Complications in Patients Undergoing Atrial Fibrillation Ablation. American Journal of Cardiology, 2013, 111, 368-373.	1.6	56
58	Ion Channel and Structural Remodeling in Obesity-Mediated Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008296.	4.8	53
59	Differential impact of race and risk factors on incidence of atrial fibrillation. American Heart Journal, 2011, 162, 31-37.	2.7	52
60	Suppression of Spontaneous Ca Elevations Prevents Atrial Fibrillation in Calsequestrin 2-Null Hearts. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 313-320.	4.8	52
61	Effect of Omega-Three Polyunsaturated Fatty Acids on Inflammation, Oxidative Stress, and Recurrence of Atrial Fibrillation. American Journal of Cardiology, 2015, 115, 196-201.	1.6	52
62	Genetic and Clinical Risk Prediction Model for Postoperative Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 25-31.	4.8	49
63	Evaluation of a Prediction Model for the Development of Atrial Fibrillation in a Repository of Electronic Medical Records. JAMA Cardiology, 2016, 1, 1007.	6.1	48
64	Electrophysiologic Characterization of Calcium Handling in Human Induced Pluripotent Stem Cell-Derived Atrial Cardiomyocytes. Stem Cell Reports, 2018, 10, 1867-1878.	4.8	48
65	Race-Specific Impact of Atrial Fibrillation Risk Factors in Blacks and Whites in the Southern Community Cohort Study. American Journal of Cardiology, 2012, 110, 1637-1642.	1.6	47
66	Epinephrine-induced changes in serum potassium and cardiac repolarization and effects of pretreatment with propranolol and diltiazem. American Journal of Cardiology, 1996, 77, 1351-1355.	1.6	46
67	2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities. Journal of Thoracic and Cardiovascular Surgery, 2012, 144, e127-e145.	0.8	44
68	Persistent Atrial Fibrillation Is Associated With Reduced Risk of Torsades de Pointes in Patients With Drug-Induced Long QT Syndrome. Journal of the American College of Cardiology, 2008, 51, 836-842.	2.8	43
69	Tremor-Induced ECG Artifact Mimicking Ventricular Tachycardia. Circulation, 2000, 102, 1337-1338.	1.6	42
70	Functional modeling in zebrafish demonstrates that the atrial-fibrillation-associated gene <i>GREM2</i> regulates cardiac laterality, cardiomyocyte differentiation and atrial rhythm. DMM Disease Models and Mechanisms, 2013, 6, 332-41.	2.4	42
71	Whole-exome sequencing in familial atrial fibrillation. European Heart Journal, 2014, 35, 2477-2483.	2.2	42
72	Coding variants in RPL3L and MYZAP increase risk of atrial fibrillation. Communications Biology, 2018, 1, 68.	4.4	42

#	Article	lF	Citations
73	Dietary salt increases first-pass elimination of oral quinidine*. Clinical Pharmacology and Therapeutics, 1997, 61, 292-300.	4.7	40
74	Arrhythmogenic right ventricular cardiomyopathy due to a novel plakophilin 2 mutation: Wide spectrum of disease in mutation carriers within a family. Heart Rhythm, 2006, 3, 939-944.	0.7	40
75	Selective Targeting of Gain-of-Function KCNQ1 Mutations Predisposing to Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2013, 6, 960-966.	4.8	40
76	Characterization of Genome-Wide Association-Identified Variants for Atrial Fibrillation in African Americans. PLoS ONE, 2012, 7, e32338.	2.5	37
77	Mendelian randomization supports bidirectional causality between telomere length and clonal hematopoiesis of indeterminate potential. Science Advances, 2022, 8, eabl6579.	10.3	36
78	Modulation by Dietary Salt of Verapamil Disposition in Humans. Circulation, 1998, 98, 2702-2708.	1.6	31
79	Effect of Peripheral Arterial Disease in Patients Undergoing Percutaneous Coronary Intervention With Intracoronary Stents. Mayo Clinic Proceedings, 2004, 79, 1113-1118.	3.0	30
80	Genetics of atrial fibrillation: Rare mutations, common polymorphisms, and clinical relevance. Heart Rhythm, 2008, 5, 483-486.	0.7	30
81	Genetic Susceptibility for Atrial Fibrillation in Patients Undergoing Atrial Fibrillation Ablation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e007676.	4.8	30
82	Association of Rare Genetic Variants and Early-Onset Atrial Fibrillation in Ethnic Minority Individuals. JAMA Cardiology, 2021, 6, 811.	6.1	30
83	Prediction of late cardiac events by dipyridamole thallium scintigraphy in patients with intermittent claudication and occult coronary artery disease. American Journal of Cardiology, 1996, 78, 736-740.	1.6	29
84	Symptomatic burden as an endpoint to evaluate interventions in patients with atrial fibrillation. Heart Rhythm, 2005, 2, 544-549.	0.7	29
85	Genetic determinants of telomere length from 109,122 ancestrally diverse whole-genome sequences in TOPMed. Cell Genomics, 2022, 2, 100084.	6.5	29
86	Human induced pluripotent stem cell-derived atrial cardiomyocytes carrying an SCN5A mutation identify nitric oxide signaling as a mediator of atrial fibrillation. Stem Cell Reports, 2021, 16, 1542-1554.	4.8	25
87	Pharmacogenetics of antiarrhythmic therapy. Expert Opinion on Pharmacotherapy, 2006, 7, 1583-1590.	1.8	24
88	A Rate-Independent Method of Assessing QT-RR Slope Following Conversion of Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2007, 18, 636-641.	1.7	24
89	ACE I/D polymorphism associated with abnormal atrial and atrioventricular conduction in lone atrial fibrillation and structural heart disease: Implications for electrical remodeling. Heart Rhythm, 2009, 6, 1327-1332.	0.7	24
90	Common SCN10A variants modulate PR interval and heart rate response during atrial fibrillation. Europace, 2014, 16, 485-490.	1.7	24

#	Article	IF	Citations
91	The AFFORD Clinical Decision Aid to Identify Emergency Department Patients With Atrial Fibrillation at Low Risk for 30-Day Adverse Events. American Journal of Cardiology, 2015, 115, 763-770.	1.6	24
92	Risk Factors for Bradycardia Requiring Pacemaker Implantation in Patients With Atrial Fibrillation. American Journal of Cardiology, 2012, 110, 1315-1321.	1.6	23
93	Association Between Family History and Early-Onset Atrial Fibrillation Across Racial and Ethnic Groups. JAMA Network Open, 2018, 1, e182497.	5.9	23
94	Variants in the $\langle i \rangle$ SCN5A $\langle i \rangle$ Promoter Associated With Various Arrhythmia Phenotypes. Journal of the American Heart Association, 2016, 5, .	3.7	22
95	Association Between Obesity-Mediated Atrial Fibrillation and Therapy With Sodium Channel Blocker Antiarrhythmic Drugs. JAMA Cardiology, 2020, 5, 57.	6.1	22
96	Future of antiarrhythmic drugs. Current Opinion in Cardiology, 2006, 21, 361-367.	1.8	21
97	A Common Variant on Chromosome 4q25 is Associated With Prolonged PR Interval in Subjects With and Without Atrial Fibrillation. American Journal of Cardiology, 2014, 113, 309-313.	1.6	20
98	Localization of the Origin of Arrhythmias for Ablation: From Electrocardiography to Advanced Endocardial Mapping Systems. Journal of Cardiovascular Electrophysiology, 2001, 12, 1309-1325.	1.7	19
99	The "missing―link in atrial fibrillation heritability. Journal of Electrocardiology, 2011, 44, 641-644.	0.9	19
100	Electrophysiologic and molecular mechanisms of a frameshift NPPA mutation linked with familial atrial fibrillation. Journal of Molecular and Cellular Cardiology, 2019, 132, 24-35.	1.9	19
101	Genomics, heart failure and sudden cardiac death. Heart Failure Reviews, 2010, 15, 229-238.	3.9	17
102	Evaluating the HATCH score for predicting progression to sustained atrial fibrillation in ED patients with new atrial fibrillation. American Journal of Emergency Medicine, 2013, 31, 792-797.	1.6	17
103	Candidate gene approach to identifying rare genetic variants associated with lone atrial fibrillation. Heart Rhythm, 2014, $11$ , $46-52$ .	0.7	17
104	Clinical use of and future perspectives on antiarrhythmic drugs. European Journal of Clinical Pharmacology, 2008, 64, 1139-1146.	1.9	16
105	The Role of Pharmacogenetics in Atrial Fibrillation Therapeutics. Journal of Cardiovascular Pharmacology, 2016, 67, 9-18.	1.9	16
106	Sympathetic Activation Enhances QT Prolongation by Quinidine. Journal of Cardiovascular Electrophysiology, 2001, 12, 9-14.	1.7	15
107	Implantable Cardioverter-Defibrillator Malfunction due to Mechanical Failure of the Header Connection. Journal of Cardiovascular Electrophysiology, 2004, 15, 1095-1099.	1.7	15
108	A Genotype-Dependent Intermediate ECG Phenotype in Patients With Persistent Lone Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2009, 2, 24-28.	4.8	15

#	Article	IF	Citations
109	A Genome-Wide Association Study to Identify Genomic Modulators of Rate Control Therapy in Patients With Atrial Fibrillation. American Journal of Cardiology, 2014, 114, 593-600.	1.6	15
110	The "Double―Paradox of Atrial Fibrillation in Black Individuals. JAMA Cardiology, 2016, 1, 377.	6.1	15
111	Sotalol-induced torsades de pointes precipitated during treatment with oseltamivir for H1N1 influenza. Heart Rhythm, 2010, 7, 1454-1457.	0.7	14
112	Improved understanding of the pathophysiology of atrial fibrillation through the lens of discrete pathological pathways. Global Cardiology Science & Practice, 2014, 2014, 5.	0.4	14
113	Mortality Among Patients With Early-Onset Atrial Fibrillation and Rare Variants in Cardiomyopathy and Arrhythmia Genes. JAMA Cardiology, 2022, 7, 733.	6.1	14
114	On the relationship among QT interval, atrial fibrillation, and torsade de pointes. Europace, 2007, 9, iv1-iv3.	1.7	13
115	Severity of Obstructive Sleep Apnea Influences the Effect of Genotype on Response to Anti-Arrhythmic Drug Therapy for Atrial Fibrillation. Journal of Clinical Sleep Medicine, 2014, 10, 503-507.	2.6	13
116	Atrial Fibrillation and SCN5A Variants. Cardiac Electrophysiology Clinics, 2014, 6, 741-748.	1.7	13
117	Genetic heterogeneity of atrial fibrillation susceptibility loci across racial or ethnic groups. European Heart Journal, 2017, 38, 2595-2598.	2.2	13
118	Common genetic variants associated with obesity in an African-American and Hispanic/Latino population. PLoS ONE, 2021, 16, e0250697.	2.5	13
119	Proarrhythmic and Torsadogenic Effects of Potassium Channel Blockers in Patients. Cardiac Electrophysiology Clinics, 2016, 8, 481-493.	1.7	12
120	Genetic modulation of atrial fibrillation risk in a Hispanic/Latino cohort. PLoS ONE, 2018, 13, e0194480.	2.5	12
121	Prevalence and Predictors of Atrial Fibrillation Among Patients Undergoing Bariatric Surgery. Obesity Surgery, 2014, 24, 611-616.	2.1	11
122	Genetics of atrial fibrillationâ€"practical applications for clinical management: if not now, when and how?. Cardiovascular Research, 2021, 117, 1718-1731.	3.8	11
123	Mutant ANP induces mitochondrial and ion channel remodeling in a human iPSC–derived atrial fibrillation model. JCI Insight, 2022, 7, .	5.0	11
124	Examining Rare and Low-Frequency Genetic Variants Previously Associated With Lone or Familial Forms of Atrial Fibrillation in an Electronic Medical Record System. Circulation: Cardiovascular Genetics, 2015, 8, 58-63.	5.1	10
125	Genetic Risk Scores for Atrial Fibrillation: Do They Improve Risk Estimation?. Canadian Journal of Cardiology, 2017, 33, 422-424.	1.7	10
126	Rare variants in genes encoding the cardiac sodium channel and associated compounds and their impact on outcome of catheter ablation of atrial fibrillation. PLoS ONE, 2017, 12, e0183690.	2.5	10

#	Article	IF	CITATIONS
127	Atrial fibrillation and flutter outcomes and risk determination (AFFORD): Design and rationale. Journal of Cardiology, 2011, 58, 124-130.	1.9	9
128	Himalayan T Waves in the Congenital Long-QT Syndrome. Circulation, 2005, 111, e161.	1.6	8
129	Is it time to develop a "pathogenicity―score to distinguish long QT syndrome causing mutations from "background―genetic noise?. Heart Rhythm, 2009, 6, 1304-1305.	0.7	8
130	Investigating the Genetic Architecture of the PR Interval Using Clinical Phenotypes. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	8
131	Relation of Body Mass Index to Symptom Burden in Patients withAtrial Fibrillation. American Journal of Cardiology, 2018, 122, 235-241.	1.6	8
132	GWAS of QRS duration identifies new loci specific to Hispanic/Latino populations. PLoS ONE, 2019, 14, e0217796.	2.5	8
133	Pathogenic mutations perturb calmodulin regulation of Nav1.8 channel. Biochemical and Biophysical Research Communications, 2020, 533, 168-174.	2.1	8
134	Arrhythmia Pharmacogenomics: Methodological Considerations. Current Pharmaceutical Design, 2009, 15, 3734-3741.	1.9	7
135	Lone AF - Etiologic Factors and Genetic Insights into Pathophysiolgy. Journal of Atrial Fibrillation, 2010, 3, 236.	0.5	7
136	The Value of Rare Genetic Variation in the Prediction of Common Obesity in European Ancestry Populations. Frontiers in Endocrinology, 2022, 13, 863893.	3.5	7
137	ATTITUDES OF PHYSICIANS IN THE TREATMENT OF CONGESTIVE HEART FAILURE IN OLDER ADULTS. Journal of the American Geriatrics Society, 1995, 43, 943-944.	2.6	6
138	Can qualitative echocardiography be used to select patients for angiotensin-converting enzyme inhibitors following acute myocardial infarction?. European Heart Journal, 1996, 17, 1783-1785.	2.2	6
139	Relation of Obstructive Sleep Apnea and a Common Variant at Chromosome 4q25 to Atrial Fibrillation. American Journal of Cardiology, 2017, 119, 1387-1391.	1.6	6
140	Bioengineering approaches to mature induced pluripotent stem cell-derived atrial cardiomyocytes to model atrial fibrillation. Experimental Biology and Medicine, 2021, 246, 1816-1828.	2.4	6
141	Loss of quinidine gluconate injection in a polyvinyl chloride infusion system. American Journal of Health-System Pharmacy, 1996, 53, 655-658.	1.0	5
142	Recurrence of Atrial Tachyarrhythmias in Implantable Cardioverter-Defibrillator Recipients. PACE - Pacing and Clinical Electrophysiology, 2005, 28, 1047-1051.	1.2	5
143	Congenital long QT syndrome aggravated by salt-wasting nephropathy. Heart Rhythm, 2005, 2, 304-306.	0.7	5
144	Cardiac sodium channel variants: Action players with many faces. Heart Rhythm, 2008, 5, 1441-1443.	0.7	5

#	Article	IF	CITATIONS
145	Genome-Wide Assessment for Genetic Variants Associated with Ventricular Dysfunction after Primary Coronary Artery Bypass Graft Surgery. PLoS ONE, 2011, 6, e24593.	2.5	5
146	Genotype influence in responses to therapy for atrial fibrillation. Expert Review of Cardiovascular Therapy, 2016, 14, 1119-1131.	1.5	5
147	Association of atrial fibrillation risk alleles and response to acute rate control therapy. American Journal of Emergency Medicine, 2016, 34, 735-740.	1.6	5
148	Whole Genome Sequencing Identifies CRISPLD2 as a Lung Function Gene in Children With Asthma. Chest, 2019, 156, 1068-1079.	0.8	5
149	Clinical and Genetic Contributors to New-Onset Atrial Fibrillation in Critically Ill Adults*. Critical Care Medicine, 2020, 48, 22-30.	0.9	5
150	Impact of traditional risk factors for the outcomes of atrial fibrillation across race and ethnicity and sex groups. IJC Heart and Vasculature, 2020, 28, 100538.	1.1	5
151	Common genetic variation in circadian clock genes are associated with cardiovascular risk factors in an African American and Hispanic/Latino cohort. IJC Heart and Vasculature, 2021, 34, 100808.	1.1	5
152	Heart failure: a diagnostic and therapeutic dilemma in elderly patients. Age and Ageing, 1998, 27, 539-543.	1.6	4
153	P1-84. Heart Rhythm, 2006, 3, S135-S136.	0.7	4
154	Triggers for cardiac events in patients with type 2 long QT syndrome. Heart Rhythm, 2010, 7, 1806-1807.	0.7	4
155	Measurement of diffuse ventricular fibrosis with myocardial T1 in patients with atrial fibrillation. Journal of Arrhythmia, 2016, 32, 51-56.	1.2	4
156	Standard Antiarrhythmic Drugs. , 2018, , 1062-1075.		4
157	Multi-Ethnic Genome-Wide Association Study of Decomposed Cardioelectric Phenotypes Illustrates Strategies to Identify and Characterize Evidence of Shared Genetic Effects for Complex Traits. Circulation Genomic and Precision Medicine, 2020, 13, e002680.	3.6	4
158	Standard Antiarrhythmic Drugs. , 2014, , 1095-1110.		3
159	A new paradigm for predicting risk of Torsades de Pointes during drug development: Commentary on: "Improved prediction of drugâ€induced Torsades de Pointes through simulations of dynamics and machine learning algorithmsâ€i Clinical Pharmacology and Therapeutics, 2016, 100, 324-326.	4.7	3
160	Atrial Fibrillation in Inherited Channelopathies. Cardiac Electrophysiology Clinics, 2021, 13, 155-163.	1.7	3
161	Abstract 4099: Genetic and Clinical Predictors of Response to Rate Control Therapy in Patients with Atrial Fibrillation. Circulation, 2008, 118, .	1.6	3
162	Localized Aortic Dissection: Unusual Features by Transesophageal Echocardiography. Journal of the American Society of Echocardiography, 2000, 13, 1130-1134.	2.8	2

#	Article	IF	CITATIONS
163	Congenital right coronary artery aneurysm causing myocardial infarction, pseudoaneurysm formation, and right atrial compression. Journal of the American Society of Echocardiography, 2002, 15, 736-738.	2.8	2
164	Screening for genomic alterations in congenital long QT syndrome. Heart Rhythm, 2006, 3, 56-57.	0.7	2
165	Repolarization Recipes for Atrial Fibrillation. Journal of the American College of Cardiology, 2012, 59, 1026-1028.	2.8	2
166	Gene-guided therapy for catheter-ablation of atrial fibrillation: are we there yet?. Journal of Interventional Cardiac Electrophysiology, 2016, 45, 3-5.	1.3	2
167	Race and Socioeconomic Status Regulate Lifetime Risk of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e006584.	4.8	2
168	Unraveling the genomic basis of congenital heart disease. Journal of Clinical Investigation, 2021, 131, .	8.2	2
169	Abstract 356: Loss of Function Mutations of Sodium Channel Beta-1 and Beta-2 Subunits Associated with Atrial Fibrillation and ST-segment Elevation. Circulation, 2007, 116, .	1.6	2
170	Sodium Channel Variants Associated with Atrial Fibrillation Exhibit Abnormal Fast and Slow Inactivation. Biophysical Journal, 2010, 98, 310a.	0.5	1
171	Novel ECG markers for ventricular repolarization: Is the QT interval obsolete?. Heart Rhythm, 2011, 8, 1044-1045.	0.7	1
172	Assessment of the Framingham risk factors among ED patients with newly diagnosed atrial fibrillation. American Journal of Emergency Medicine, 2012, 30, 151-157.	1.6	1
173	The Pharmacogenomics of a Mutation "Hotspot―for the Short QT Syndrome. JACC: Clinical Electrophysiology, 2017, 3, 744-746.	3.2	1
174	Is Achieving the American Heart Association's Life Simple 7 Goals Sufficient to Reduce the Burden of Atrial Fibrillation? No Simple Answers. Journal of the American Heart Association, 2018, 7, .	3.7	1
175	Deciphering the Electrophysiological Mechanisms for Ibrutinib-Induced Ventricular Arrhythmias. JACC: CardioOncology, 2020, 2, 630-631.	4.0	1
176	Atrial Fibrillation and Longitudinal Change in Cognitive Function in CKD. Kidney International Reports, 2021, 6, 669-674.	0.8	1
177	Genetic and Molecular Basis of Arrhythmias. , 2011, , 65-86.		1
178	Atrial Fibrillation Susceptibility Alleles on Chromosome 4q25 Modulate Response to Catheter Ablation. Journal of Atrial Fibrillation, 2010, 3, 272.	0.5	1
179	Predicting Ejection Fraction after Myocardial Infarction. Annals of Internal Medicine, 1995, 122, 729.	3.9	0
180	AB5-4. Heart Rhythm, 2006, 3, S10.	0.7	0

#	Article	IF	CITATIONS
181	A Shock in Time. Clinical Journal of Sport Medicine, 2007, 17, 497-499.	1.8	0
182	Response to Letter Regarding Article, $\hat{a} \in \infty$ Cardiac Sodium Channel ( SCN5A ) Variants Associated with Atrial Fibrillation $\hat{a} \in \mathbb{R}$ Circulation, 2008, 118, .	1.6	0
183	Genomics and Atrial Arrhythmias. , 0, , 65-79.		O
184	Symptomatic Response to Antiarrhythmic Drug Therapy is Modulated by a Common Single Nucleotide Polymorphism in Atrial Fibrillation. Heart Rhythm, 2010, 7, 1721-1722.	0.7	0
185	Genomics of the Drug-Induced Long-QT Syndrome. , 0, , 136-144.		0
186	Germline versus somatic mutations in genetic atrial fibrillation. Heart Rhythm, 2017, 14, 1539-1540.	0.7	0
187	RHYTHM DISORDERS., 2009, , 367-387.		O
188	Algorithm to detect left ventricular dysfunction after myocardial infarction. BMJ: British Medical Journal, 1996, 312, 579-579.	2.3	0
189	Genetic and Molecular Basis of Cardiac Arrhythmias. Contemporary Cardiology, 2020, , 75-96.	0.1	O
190	The Burden of Atrial Fibrillation in Sickle Cell Disease. Blood, 2021, 138, 3119-3119.	1.4	0